Allergy Immunotherapy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Allergy immunotherapy — also known as allergen desensitisation or hyposensitisation — is the only currently available treatment that modifies the underlying immune mechanism of IgE-mediated allergic disease rather than merely suppressing symptoms. It works by administering progressively increasing doses of a specific allergen extract to gradually reprogram the immune system's response, shifting it from a Th2-dominant inflammatory profile toward a regulatory immune response characterised by increased production of blocking IgG4 antibodies and regulatory T cells.

The treatment has been in clinical use for over a century since Leonard Noon's landmark work in 1911 and is now endorsed by the World Allergy Organization, EAACI, and NICE as a first-line disease-modifying therapy for specific indications. It is delivered in two main formats: subcutaneous immunotherapy (SCIT), administered as injections in a clinic setting, and sublingual immunotherapy (SLIT), taken as drops or dissolvable tablets under the tongue at home. A full course typically spans 3–5 years.

Clinically, immunotherapy produces lasting benefit that persists for several years after the course is completed — a key advantage over pharmacotherapy which only suppresses symptoms during active use. Patients typically undergo an initial build-up phase over several weeks (SCIT) or months (SLIT), followed by a maintenance phase. The treatment journey requires commitment and regular monitoring, particularly for SCIT which carries a small risk of anaphylaxis necessitating clinic-based administration with post-injection observation.

Allergic rhinoconjunctivitis (hay fever) caused by grass pollen, house dust mite, tree pollen, or animal danders is the primary indication for allergen immunotherapy. Clinical trials demonstrate 30–40% reduction in total symptom scores and medication use compared with placebo. Both SCIT and SLIT (particularly standardised tablets for grass, house dust mite, and tree pollen) are licensed for this indication and have robust long-term data.

Allergic asthma driven by defined allergen sensitisation is a secondary indication, with immunotherapy shown to reduce asthma exacerbation rates, bronchial hyperresponsiveness, and medication requirements. Venom immunotherapy for insect sting allergy (bee, wasp) is the most life-saving application, reducing the risk of systemic anaphylaxis on re-sting from 40–60% to less than 5% — a clinically dramatic benefit that is maintained for many years after treatment completion. Immunotherapy for food allergies, particularly peanut oral immunotherapy, is an emerging field with licensed therapies now available in several countries.

Ideal candidates for allergen immunotherapy are individuals with IgE-mediated allergic disease confirmed by positive skin prick tests or specific IgE blood tests, in whom allergen avoidance and pharmacotherapy have failed to provide adequate symptom control or impose unacceptable quality-of-life burden. Patients should have a clear correlation between allergen exposure and symptom onset, a defined sensitisation to one or a small number of clinically relevant allergens, and the motivation to commit to a multi-year treatment course. Children above 5 years of age and adults of all ages are eligible.

Contraindications include severe or unstable asthma (FEV1 below 70% predicted), significant cardiovascular disease (due to the risk of impaired anaphylaxis rescue with adrenaline), concurrent use of beta-blockers or ACE inhibitors (which can potentiate reactions and impair treatment of anaphylaxis), active autoimmune disease, malignancy, and pregnancy (initiating new courses is contraindicated, though established maintenance courses can usually be continued). Patients with severe or uncontrolled atopic dermatitis may have reduced SCIT tolerability.

Subcutaneous immunotherapy (SCIT) involves a build-up phase of weekly or twice-weekly clinic injections with escalating allergen doses over 3–6 months, followed by monthly maintenance injections for 3–5 years. Cluster and rush protocols allow accelerated build-up over days to weeks. SCIT delivers the highest degree of immune tolerance and is the gold standard for venom allergy and complex multi-sensitised cases. Post-injection observation for 30 minutes in a clinic equipped with resuscitation facilities is mandatory.

Sublingual immunotherapy (SLIT) is delivered as daily allergen drops or dissolvable tablets placed under the tongue for 1–2 minutes then swallowed. Standardised sublingual tablets are available for grass pollen (Grazax, Itulazax), house dust mite (Acarizax), and tree pollen in many countries. SLIT offers the major advantage of home administration, improved compliance, and a superior safety profile compared to SCIT. It is preferred for children and patients in whom SCIT is logistically challenging. Both routes of administration are increasingly being offered by specialist allergy centres in India, Thailand, and Eastern Europe as part of medical tourism programmes.

Selecting the most appropriate Allergy Immunotherapy approach requires a structured assessment of patient-specific factors. The treating specialist evaluates disease severity, prior treatment history, comorbidities, and patient preferences before recommending a specific protocol. Combination approaches are often more effective than monotherapy — integrating pharmacological, procedural, or rehabilitative elements to address multiple disease mechanisms simultaneously. Dose or intensity is titrated incrementally based on clinical response, tolerability, and objective outcome measures. In patients with refractory disease or inadequate response to first-line protocols, escalation to higher-intensity or specialist-delivered treatment options is indicated. Multidisciplinary team (MDT) review ensures that surgical, medical, and allied health perspectives are integrated into the final management plan, particularly for complex or high-risk cases where multiple treatment pathways are viable and the risk-benefit balance requires careful deliberation.

The defining benefit of allergen immunotherapy is disease modification — the ability to produce lasting clinical tolerance that persists after treatment completion. Meta-analyses of SCIT and SLIT for allergic rhinitis demonstrate statistically and clinically significant reductions in symptom scores and medication use versus placebo. Long-term follow-up studies show that benefits from a completed 3-year SCIT course persist for at least 3–6 additional years after cessation — a benefit profile not achievable with antihistamines or corticosteroids.

For venom immunotherapy, protection against life-threatening anaphylaxis on re-sting is achieved in over 95% of treated patients. In asthma, immunotherapy reduces exacerbation rates and may prevent new sensitisations in children, potentially modifying the long-term atopic march. Quality-of-life improvements in well-selected patients are substantial: reduced medication burden, fewer sick days, improved sleep, and reduced anxiety around allergen exposure. Some trials have shown prevention of asthma development in children with allergic rhinitis treated with grass pollen SLIT.

SCIT carries a defined risk of local reactions (swelling, redness at injection site) in approximately 10–30% of injections, and systemic reactions ranging from mild urticaria to anaphylaxis in approximately 1 in 1 million injections. Fatalities are extremely rare (estimated at 1 in 2 million injections) and almost exclusively occur in patients with uncontrolled severe asthma who receive injections during acute exacerbations — an absolute contraindication. Post-injection observations and on-site adrenaline availability are mandatory safeguards.

SLIT carries a considerably safer profile, with systemic reactions being rare. The most common adverse effects are local oropharyngeal reactions (itching, tingling in the mouth) which are mild and typically resolve within weeks of initiating therapy. Severe anaphylaxis has been reported in very rare cases with SLIT, particularly during the first dose. General risks applicable to the full course include the time commitment (3–5 years), cost considerations without insurance coverage, and the requirement for a maintenance schedule that patients must adhere to for maximal benefit.

Immunotherapy is not a procedure with a distinct recovery period but requires structured long-term clinical monitoring. Patients on SCIT attend clinic every 1–4 weeks during build-up and monthly during maintenance, with annual clinical review to assess symptom control, adjust doses if needed, and determine whether the full 3–5 year course has been completed. Annual spirometry is advisable for asthmatic patients. SLIT patients are typically reviewed at 3 and 12 months during the first year, then annually.

Patients should maintain symptom diaries and continue to carry an adrenaline auto-injector (for venom allergy patients) throughout treatment. Antihistamines should be available for breakthrough symptoms. At the end of the treatment course, the decision to continue or stop is made based on degree of clinical tolerance achieved. Many patients achieve sustained remission; those with ongoing severe sensitisation may require a repeat course or indefinite low-dose maintenance. Lifestyle modifications such as continued allergen avoidance during pollen season (appropriate clothing, nasal filters) complement immunotherapy.

The cost of a full allergen immunotherapy course varies significantly by country and route. In the United States, SCIT over 3–5 years can cost $3,000–10,000 in total (including consultations, extracts, and clinic fees), while SLIT tablets such as Grazax cost approximately $1,200–2,000 per year. Many US health insurance plans cover immunotherapy for allergic rhinitis and asthma. In the UK, NHS-funded allergy clinics provide SCIT and standardised SLIT free at point of care for eligible patients, though waiting times can be lengthy.

Patients seeking immunotherapy abroad can access high-quality care at significantly lower cost. In India, specialist allergy centres in major cities such as Delhi, Mumbai, and Bangalore offer complete SCIT programmes (consultation, testing, and injections) for $500–2,000 per year — a saving of 60–80% compared to the US. Turkey, Poland, and Thailand offer comparable programmes with internationally trained allergists at 40–70% of Western prices. Medical tourism for immunotherapy initiation combined with home-country continuation is an increasingly viable model.

The primary alternative to allergen immunotherapy is ongoing pharmacological symptom management with second-generation antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists. These agents effectively control symptoms but do not modify the underlying disease and require continuous use. Anti-IgE biologic therapy (omalizumab) is an effective option for severe allergic asthma and chronic urticaria but is not typically used for isolated allergic rhinitis.

Non-pharmacological alternatives include rigorous allergen avoidance strategies — HEPA filters, encasings for house dust mite, relocating pets — which reduce allergen load but are rarely sufficient alone for moderate-to-severe disease. For patients who cannot tolerate or commit to immunotherapy, symptom management with a combination of antihistamines, nasal steroids, and eye drops remains a valid and effective approach. Immunotherapy is preferred when the goal is long-term disease modification and reduction in medication dependency.